07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Algisyl-LVR regulatory update

LoneStar Heart said it received CE Mark approval for its Algisyl-LVR hydrogel implant to treat advanced heart failure in patients with an enlarged left ventricle. The biologically inert polymer is injected into the left ventricle...
08:00 , Mar 6, 2014 |  BC Innovations  |  Tools & Techniques

Taking TIMP3 to heart

A U.S. team has found a way to harness the cardioprotective activity of tissue inhibitor of metalloproteinases 3 while avoiding its off-target effects by embedding it in a hydrogel for direct injection into the heart.1...
01:18 , Oct 10, 2012 |  BC Extra  |  Top Story

LoneStar announces series B extension

LoneStar Heart Inc. (Laguna Hills, Calif.) secured up to $20 million in an extension of a series B round led by new investor Themes Investment Partners. Existing investor Dinova Venture Partners also participated. LoneStar raised...
07:00 , Jun 25, 2012 |  BioCentury  |  Emerging Company Profile

LoneStar Heart: Straight to the heart

Therapies for heart failure are palliative and aimed primarily at delaying pathological cardiac remodeling and progression to advanced disease. LoneStar Heart Inc. is developing a trio of technologies that it believes have the potential to...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

LoneStar Heart, University of Texas Southwestern Medical Center deal

LoneStar received exclusive, worldwide rights from the university to develop and commercialize Isoxazoles for diabetes. The small molecules can increase or restore insulin production in dormant or dysfunctional pancreatic cells, and are in discovery for...